

Adriaan A Voors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4989388/publications.pdf>

Version: 2024-02-01

576
papers

73,249
citations

1171

111
h-index

693

253
g-index

607
all docs

607
docs citations

607
times ranked

46215
citing authors

#	ARTICLE	IF	CITATIONS
1	A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 743-755.	1.3	9
2	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	1.2	5
3	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
4	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	1.8	5
5	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTAT-CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	2.9	20
6	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2022, 24, 365-374.	2.9	34
7	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	2.9	9
8	Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
9	Natriuresis-guided therapy in acute heart failure: rationale and design of the <sc>Pragmatic Urinary Sodium-based treatment algorithm</sc> in <sc>Acute Heart Failure</sc> (<sc>PUSH-AHF</sc>) trial. <i>European Journal of Heart Failure</i> , 2022, 24, 385-392.	2.9	26
10	Left atrial structure and function in heart failure with reduced (HF_rEF) versus preserved ejection fraction (HF_pEF): systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2022, 27, 1933-1955.	1.7	12
11	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	1.9	115
12	Renal Compression in Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 175-183.	1.9	44
13	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
14	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	15.2	341
15	Transcatheter edge-to-edge repair of tricuspid regurgitation in the Netherlands: state of the art and future perspectives. <i>Netherlands Heart Journal</i> , 2022, 30, 393-399.	0.3	4
16	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. <i>Circulation</i> , 2022, 145, 693-712.	1.6	57
17	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	1.5	10
18	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
20	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
21	Surrogate markers of gut dysfunction are related to heart failure severity and outcome from the BIOSTAT-CHF consortium. <i>American Heart Journal</i> , 2022, 248, 108-119.	1.2	5
22	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	2.9	7
23	Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 1346-1356.	2.9	26
24	Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations. <i>European Journal of Heart Failure</i> , 2022, 24, 1418-1426.	2.9	10
25	Risk factors for the development of heart failure in patients with or without prior myocardial infarction. <i>European Journal of Heart Failure</i> , 2022, 24, 985-987.	2.9	0
26	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1009-1019.	2.9	6
27	Distinct pathophysiological pathways in women and men with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1532-1544.	2.9	10
28	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 2131-2139.	2.9	8
29	Heart failure medication: moving from evidence generation to implementation. <i>European Heart Journal</i> , 2022, 43, 2588-2590.	1.0	4
30	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	2.9	46
31	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	1.8	108
32	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021, 117, 2228-2236.	1.8	8
33	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 436-444.	2.9	20
34	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. <i>Heart Failure Reviews</i> , 2021, 26, 255-262.	1.7	0
35	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
36	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 68-78.	2.9	79
38	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
39	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
40	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
41	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	2.9	10
42	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. <i>BMC Medicine</i> , 2021, 19, 21.	2.3	5
43	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	2.9	60
44	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.4	3
45	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1211-1221.	1.2	19
46	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	2.9	13
47	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	2.9	9
48	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	2.9	15
49	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 983-991.	2.9	70
50	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	2.9	26
51	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 560-571.	0.8	40
52	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
53	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e019123.	1.6	9
54	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021, 44, 780-788.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective) Tj ETQq1 1 0.7843149gBT /Overlock 10	1.4	33
56	Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 1049-1052.	2.9	2
57	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, 8, 3168-3179.	1.4	33
58	Post-transplant inotrope score is associated with clinical outcomes after adult heart transplantation. Clinical Transplantation, 2021, 35, e14347.	0.8	9
59	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq1 1 0.7843149gBT /Overlock 10	1.4	33
60	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	2.9	11
61	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	2.9	9
62	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676.	0.7	16
63	Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?. European Journal of Heart Failure, 2021, 23, 1437-1444.	2.9	9
64	Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association, 2021, 10, e018549.	1.6	51
65	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> trial. European Journal of Heart Failure, 2021, 23, 1300-1312.	2.9	35
66	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	0.7	7
67	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686.	2.9	11
68	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	2.0	32
69	Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review. Circulation: Heart Failure, 2021, 14, e008064.	1.6	11
70	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTAT-CHF</scp>. European Journal of Heart Failure, 2021, 23, 1750-1758.	2.9	32
71	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	1.6	21
72	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	1.0	33

#	ARTICLE	IF	CITATIONS
73	Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals. <i>ELife</i> , 2021, 10, .	2.8	6
74	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
75	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021, 27, 934-941.	0.7	0
76	Amended <sc>STRONG–HF</sc> study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	2.9	8
77	Chloride in Heart–Failure. <i>JACC: Heart Failure</i> , 2021, 9, 904-915.	1.9	22
78	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart–Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	1.9	7
79	Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study. <i>American Heart Journal</i> , 2021, 244, 36-41.	1.2	0
80	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008548.	1.6	11
81	Proenkephalin and the risk of new–onset heart failure: data from prevention of renal and vascular end–stage disease. <i>Clinical Cardiology</i> , 2021, , .	0.7	4
82	Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction. <i>Circulation</i> , 2021, 144, .	1.6	0
83	Abstract 11074: Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response. <i>Circulation</i> , 2021, 144, .	1.6	0
84	128–Clinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
85	Abstract 12543: Limited Blood Biomarker Changes After Reverse Remodelling: A Markers and Response to CRT (Marc) Substudy. <i>Circulation</i> , 2021, 144, .	1.6	0
86	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	1.5	28
87	Plasma proteomic approach in patients with–heart failure: insights into pathogenesis of–disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	2.9	28
88	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , 2020, 71, 62-69.	1.0	12
89	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	2.9	50
90	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2020, 133, 370-380.e4.	0.6	58

#	ARTICLE	IF	CITATIONS
91	Improving risk prediction in heart failure using machine learning. <i>European Journal of Heart Failure</i> , 2020, 22, 139-147.	2.9	132
92	Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-CHF). <i>European Journal of Heart Failure</i> , 2020, 22, 713-722.	2.9	260
93	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	2.9	15
94	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-CHF registry. <i>European Journal of Heart Failure</i> , 2020, 22, 751-754.	2.9	4
95	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
96	Clinical value of pre-discharge bioadrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	2.9	33
97	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1415-1423.	2.9	84
98	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2020, 22, 81-89.	2.9	15
99	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	2.9	24
100	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
101	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <sc>GALACTIC-CHF</sc> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
102	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
103	Implications of serial measurements of natriuretic peptides in heart failure: insights from <sc>BIOSTAT-CHF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1486-1490.	2.9	7
104	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	1.9	12
105	Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes. <i>European Heart Journal</i> , 2020, 41, 3099-3099.	1.0	8
106	Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration. <i>Circulation</i> , 2020, 142, 1117-1119.	1.6	16
107	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4047-4049.	1.0	7
108	A combined bioinformatics, experimental and clinical approach to identify novel cardiac-specific heart failure biomarkers: is Dickkopf-3 (DKK3) a possible candidate?. <i>European Journal of Heart Failure</i> , 2020, 22, 2065-2074.	2.9	10

#	ARTICLE	IF	CITATIONS
109	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. <i>Nutrients</i> , 2020, 12, 2541.	1.7	16
110	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1108-1109.	0.7	0
111	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006731.	1.6	37
112	Angiotensin-converting enzyme 2 (<sc>ACE2</sc>), <sc>SARS-CoV-2</sc> and the pathophysiology of coronavirus disease 2019 (<sc>COVID-19</sc>). <i>Journal of Pathology</i> , 2020, 251, 228-248.	2.1	791
113	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	1.0	381
114	Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study. <i>Journal of Hypertension</i> , 2020, 38, 1064-1071.	0.3	6
115	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020, 7, 1419-1429.	1.4	6
116	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. <i>Nature Reviews Cardiology</i> , 2020, 17, 641-655.	6.1	143
117	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
118	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1649-1658.	2.9	49
119	Should Enrichment With Natriuretic Peptide Levels Be Mandatory in Global Clinical Trials?. <i>JACC: Heart Failure</i> , 2020, 8, 369-371.	1.9	2
120	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2020, 141, 1915-1926.	1.6	40
121	Clinical Role of CA125 in Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 386-397.	1.9	57
122	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	1.0	47
123	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial-Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
124	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
125	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020, 7, 953-963.	1.4	9
126	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	2.9	193

#	ARTICLE	IF	CITATIONS
127	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-CHF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	2.9	21
128	Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 667-676.	1.9	45
129	Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?. <i>European Heart Journal</i> , 2020, 41, 3096-3096.	1.0	15
130	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-CHF registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	2.9	24
131	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	0.7	46
132	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	1.9	25
133	Clinical importance of urinary sodium excretion in acute heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1438-1447.	2.9	55
134	β_1 -Adrenoreceptor Autoantibodies in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006155.	1.6	29
135	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	1.5	7
136	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 903-906.	2.9	3
137	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 821-833.	2.9	28
138	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2353-2355.	1.0	31
139	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
140	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	1.5	20
141	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	2.9	34
142	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	13.9	174
143	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	0.7	16
144	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019, 21, 1291-1294.	2.9	25

#	ARTICLE	IF	CITATIONS
145	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. ESC Heart Failure, 2019, 6, 1188-1198.	1.4	22
146	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	2.9	9
147	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure, 2019, 21, 1426-1433.	2.9	27
148	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
149	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263.	6.3	159
150	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	1.0	944
151	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal, 2019, 40, 3616-3625.	1.0	69
152	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. PLoS Medicine, 2019, 16, e1002916.	3.9	64
153	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
154	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031.	2.9	20
155	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	1.6	33
156	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101.	3.8	47
157	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. JAMA Cardiology, 2019, 4, 696.	3.0	43
158	Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. Circulation, 2019, 139, 2383-2385.	1.6	1
159	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. European Journal of Heart Failure, 2019, 21, 965-973.	2.9	172
160	Time to Revisit the Value of Urine Collections in Heart Failure. JACC: Heart Failure, 2019, 7, 392-393.	1.9	0
161	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. Circulation: Heart Failure, 2019, 12, e005544.	1.6	23
162	Bioadrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. European Journal of Heart Failure, 2019, 21, 732-743.	2.9	64

#	ARTICLE	IF	CITATIONS
163	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
164	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	2.9	65
165	Sex differences in heart failure. <i>European Heart Journal</i> , 2019, 40, 3859-3868c.	1.0	406
166	Very Early Diuretic Response After Admission for Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 12-19.	0.7	18
167	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , 2019, 21, 163-171.	2.9	144
168	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTATâ€CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 218-226.	2.9	25
169	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
170	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019, 40, 705-706.	1.0	1
171	Rapid right-sided deterioration in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2019, 40, 699-702.	1.0	4
172	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	1.5	10
173	What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply. <i>European Journal of Heart Failure</i> , 2019, 21, 132-133.	2.9	0
174	Treating oxidative stress in heart failure: past, present and future. <i>European Journal of Heart Failure</i> , 2019, 21, 425-435.	2.9	407
175	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTATâ€CHF. <i>European Journal of Heart Failure</i> , 2019, 21, 877-886.	2.9	68
176	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTATâ€CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 112-120.	2.9	44
177	Risk stratification in acute heart failure: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 945-947.	2.9	0
178	Quantifying the HDL proteome by mass spectrometry: how many proteins truly associate with HDL? Reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1077-1078.	2.9	1
179	N-terminal pro-B-type natriuretic peptide and prognosis in <sc>Caucasian</sc> vs. <sc>Asian</sc> patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 279-287.	1.4	8
180	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2018, 11, e004519.	1.6	147

#	ARTICLE	IF	CITATIONS
181	Heart failure with mid-range ejection fraction: causes and consequences. <i>European Journal of Heart Failure</i> , 2018, 20, 660-662.	2.9	4
182	Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical Trials. <i>JACC: Heart Failure</i> , 2018, 6, 257-259.	1.9	2
183	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	1.2	35
184	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 637-643.	0.5	4
185	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	2.9	30
186	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	2.9	29
187	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	0.8	2
188	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	2.9	57
189	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	0.8	55
190	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
191	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	0.8	157
192	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	1.0	26
193	Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. <i>Europace</i> , 2018, 20, e1-e10.	0.7	131
194	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	2.9	54
195	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 425-432.	0.5	93
196	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	1.9	141
197	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 89-96.	2.9	48
198	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 621-627.	0.7	14

#	ARTICLE	IF	CITATIONS
199	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018, 24, 177-185.	0.7	65
200	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	2.9	42
201	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	1.2	16
202	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	1.1	6
203	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
204	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
205	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
206	Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. <i>European Journal of Heart Failure</i> , 2018, 20, 1636-1638.	2.9	11
207	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	2.9	27
208	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	0.8	140
209	Effect of isolated ultrafiltration and isovolemic dialysis on myocardial perfusion and left ventricular function assessed with ¹³ N-NH ₃ positron emission tomography and echocardiography. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F445-F452.	1.3	11
210	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
211	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. <i>European Journal of Heart Failure</i> , 2018, 20, 1205-1214.	2.9	60
212	Bioadrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1363-1365.	2.9	31
213	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	2.9	85
214	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. <i>Cardiovascular Research</i> , 2018, 114, 1871-1882.	1.8	38
215	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	1.6	58
216	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	2.9	113

#	ARTICLE	IF	CITATIONS
217	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	1.2	199
218	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
219	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	1.0	47
220	Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. <i>Theranostics</i> , 2018, 8, 4155-4169.	4.6	68
221	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1303-1311.	2.9	138
222	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	1.0	250
223	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1014-1022.	2.9	80
224	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	11
225	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	2.9	81
226	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	178
227	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	89
228	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	1.2	74
229	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	2.9	183
230	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	2.9	34
231	Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?. <i>European Journal of Heart Failure</i> , 2017, 19, 958-960.	2.9	4
232	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2428-2445.	1.2	88
233	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	0.8	42
234	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	2.9	104

#	ARTICLE	IF	CITATIONS
235	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <sc>EDIFY</sc> randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	2.9	154
236	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	1.0	102
237	Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3042-3051.	1.2	235
238	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	1.9	78
239	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69
240	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. <i>Clinical Research in Cardiology</i> , 2017, 106, 802-812.	1.5	30
241	Associations between volume status and circulating microRNAs in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1077-1078.	2.9	5
242	Comorbidities in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 35-66.	0.9	45
243	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	1.2	9
244	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 766.	1.2	2
245	Clinical and prognostic value of spot urinary creatinine in chronic heart failure—An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017, 188, 189-195.	1.2	10
246	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. <i>Clinical Research in Cardiology</i> , 2017, 106, 598-609.	1.5	66
247	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	6.1	525
248	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
249	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	1.9	129
250	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017, 19, 1651-1660.	2.9	89
251	Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	0
252	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. <i>European Journal of Heart Failure</i> , 2017, 19, 1483-1490.	2.9	42

#	ARTICLE	IF	CITATIONS
253	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	1.2	43
254	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	2.9	67
255	Atrial Fibrillation in Heart Failure —. <i>JACC: Heart Failure</i> , 2017, 5, 575-577.	1.9	9
256	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO ₂ Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2017, 23, 777-782.	0.7	34
257	The Fastest Way to the Failing Heart Is Through the Kidneys. <i>JACC: Heart Failure</i> , 2017, 5, 682-683.	1.9	1
258	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	36
259	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	2.9	53
260	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
261	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	1.3	8
262	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	1.5	17
263	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017, 19, 348-356.	2.9	38
264	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	0.7	30
265	Dynamics of cerebral blood flow in patients with mild non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 261-268.	2.9	29
266	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017, 19, 116-125.	2.9	50
267	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i>	0.7	39
268	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, 2-9.	0.7	26
269	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <sc>BIOSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	2.9	79
270	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. <i>PLoS ONE</i> , 2017, 12, e0177242.	1.1	25

#	ARTICLE	IF	CITATIONS
271	Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study. <i>Cardiovascular Journal of Africa</i> , 2017, 28, 370-376.	0.2	5
272	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	2.9	162
273	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
274	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	2.9	69
275	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <i>European Journal of Heart Failure</i> , 2016, 18, 588-598.	2.9	242
276	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	2.9	70
277	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016, 388, 2895-2903.	6.3	229
278	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	1.9	49
279	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
280	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure – Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	0.8	6
281	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
282	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	0.8	53
283	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	0.8	11
284	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	80
285	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	2.9	32
286	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	2.9	47
287	Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?. <i>European Journal of Heart Failure</i> , 2016, 18, 113-114.	2.9	13
288	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74

#	ARTICLE	IF	CITATIONS
289	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
290	<sc>MicroRNAs</sc> in heart failure: from biomarker to target for therapy. European Journal of Heart Failure, 2016, 18, 457-468.	2.9	235
291	2016 ESC and ACC/AHA/HFSA heart failure guideline update â€” what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628.	6.1	38
292	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. European Journal of Heart Failure, 2016, 18, 1472-1487.	2.9	200
293	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	1.0	274
294	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	1.2	292
295	Partial Adenosine A1 Agonist in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 177-203.	0.9	24
296	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. European Journal of Heart Failure, 2016, 18, 814-821.	2.9	13
297	A systems <sc>BIOlogy</sc> Study to <sc>TAilored</sc> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <sc>BIOSSTATâ€CHF</sc>. European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149
298	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050.	2.9	49
299	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Oveid	0.7	26
300	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. Expert Opinion on Pharmacotherapy, 2016, 17, 1527-1538.	0.9	3
301	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35
302	Aortic valve prosthesisâ€”patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart, 2016, 102, 107-113.	1.2	10
303	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77.	1.9	45
304	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	93
305	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opinion on Investigational Drugs, 2016, 25, 117-127.	1.9	37
306	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	0.7	47

#	ARTICLE	IF	CITATIONS
307	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	0.8	34
308	Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1494-1501.	0.4	16
309	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	1.5	16
310	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 95-102.	1.7	55
311	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	6.3	373
312	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	0.8	35
313	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 145-153.	1.5	32
314	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2016, 105, 10-16.	1.5	17
315	The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2016, 11, e0168340.	1.1	12
316	Growth differentiation factor 15 (<sc>GDF</sc>â€15) in patients admitted for acute heart failure: results from the <sc>RELAXâ€AHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1133-1143.	2.9	86
317	Biomarkers and low risk in heart failure. Data from <sc>COACH</sc> and <sc>TRIUMPH</sc>. <i>European Journal of Heart Failure</i> , 2015, 17, 1271-1282.	2.9	55
318	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <sc>RELAXâ€AHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	2.9	110
319	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	2.9	24
320	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. <i>PLoS ONE</i> , 2015, 10, e0125215.	1.1	38
321	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> <i>Heart Journal</i> , 2015, 169, 693-701.e3.	1.2	16
322	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	0.5	23
323	Comparative Assessment of Short-TermÂAdverse Events in Acute Heart Failure WithÂCystatin C andÂOther Estimates ofÂRenal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
324	Diuretic response in acute heart failureâ€”pathophysiology, evaluation, and therapy. <i>Nature Reviews Cardiology</i> , 2015, 12, 184-192.	6.1	198

#	ARTICLE	IF	CITATIONS
325	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <scp>PROTECT</scp> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	2.9	48
326	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	1.9	68
327	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCEND-HF</scp>. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
328	Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
329	Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1123-1135.	1.9	50
330	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 2565-2573.	1.0	274
331	Rationale and design of Mineralocorticoid Receptor antagonist Tolerability Study in Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	2.9	74
332	Long-term cardiac abnormalities after cranial radiotherapy in childhood cancer survivors. <i>Acta Oncologica</i> , 2015, 54, 515-521.	0.8	5
333	The year in cardiology: heart failure 2014. <i>European Heart Journal</i> , 2015, 36, 421-424.	1.0	3
334	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	1.2	116
335	Diuretic response in acute heart failure – an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
336	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	1.9	44
337	HFpEF vs. HFrEF: can microRNAs advance the diagnosis?. <i>European Journal of Heart Failure</i> , 2015, 17, 351-354.	2.9	14
338	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. <i>Lancet</i> , The, 2015, 385, S26.	6.3	23
339	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
340	Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1075-1078.	0.6	9
341	Tackling Early Heart Failure Deaths and Readmissions by Estimating Congestion –. <i>JACC: Heart Failure</i> , 2015, 3, 894-895.	1.9	7
342	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	0.7	5

#	ARTICLE	IF	CITATIONS
343	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	1.2	18
344	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	1.2	26
345	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
346	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
347	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	1.6	107
348	Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. <i>Clinical Research in Cardiology</i> , 2014, 103, 976-983.	1.5	34
349	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
350	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. <i>European Heart Journal</i> , 2014, 35, 1041-1050.	1.0	90
351	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , 2014, 35, 431-441.	1.0	104
352	Long-term tricuspid valve prosthesis-related complications in patients with congenital heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 83-89.	0.6	27
353	Prognostic value of N-terminal pro-B-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 958-966.	2.9	42
354	The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 86-94.	2.9	102
355	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <sc>SHIFT</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	2.9	42
356	Hemoconcentration-guided Diuresis in Heart Failure. <i>American Journal of Medicine</i> , 2014, 127, 1154-1159.	0.6	43
357	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424
358	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
359	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
360	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from <sc>RELAX-AHF</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	2.9	134

#	ARTICLE	IF	CITATIONS
361	Low pulse pressure as a poor-man's indicator of a low cardiac index in patients with severe cardiac dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 315-321.	0.6	11
362	Prognostic Value of Plasma Neutrophil Gelatinase-Associated Lipocalin for Mortality in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 35-42.	1.6	92
363	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
364	Novel biomarkers for prediction of poor treatment response in heart failure to guide therapy. <i>Lancet, The</i> , 2014, 383, S32.	6.3	1
365	Co-morbidities in heart failure. <i>Heart Failure Reviews</i> , 2014, 19, 163-172.	1.7	48
366	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
367	Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. <i>European Heart Journal</i> , 2014, 35, 455-469.	1.0	747
368	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	1.0	276
369	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <i>LCZ696</i> , in patients with heart failure with preserved ejection fraction: an analysis of the <i>PARAMOUNT</i> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
370	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	2.9	113
371	A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine. <i>Canadian Journal of Cardiology</i> , 2014, 30, 288-295.	0.8	21
372	Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>European Journal of Heart Failure</i> , 2014, 16, 103-111.	2.9	355
373	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 457-462.	1.6	60
374	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
375	Factors Influencing the Predictive Power of Models for Predicting Mortality and/or Heart Failure Hospitalization in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 429-436.	1.9	241
376	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	1.6	60
377	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) <i>TJ ETQq1 1 0.784314 rgBT /Overlock</i>	0.7	61
378	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, S93.	0.7	0

#	ARTICLE	IF	CITATIONS
379	Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536.	1.2	0
380	Effect of Serelaxin on Mode of Death in Acute Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1591-1598.	1.2	56
381	Risk stratification for sudden cardiac death: current status and challenges for the future. European Heart Journal, 2014, 35, 1642-1651.	1.0	341
382	Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2014, 7, 994-1002.	1.6	36
383	Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. JACC: Heart Failure, 2014, 2, 84-92.	1.9	123
384	Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction and Inflammation: A Cross-sectional Study. American Journal of Kidney Diseases, 2014, 64, 265-273.	2.1	31
385	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. Journal of Cardiac Failure, 2014, 20, 407-413.	0.7	38
386	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. European Journal of Heart Failure, 2014, 16, 614-624.	2.9	71
387	The additive burden of iron deficiency in the cardiorenal anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662.	2.9	59
388	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. American Heart Journal, 2014, 168, 354-362.e2.	1.2	5
389	Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Failure Reviews, 2014, 19, 369-381.	1.7	44
390	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439.	1.3	12
391	Heart Failure in the Young. Journal of the American College of Cardiology, 2013, 62, 1855-1856.	1.2	4
392	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure, 2013, 1, 417-424.	1.9	87
393	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. European Heart Journal, 2013, 34, 3128-3136.	1.0	56
394	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1177-1183.	1.2	78
395	The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2013, 22, 1041-1047.	1.9	23
396	HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. Journal of the American College of Cardiology, 2013, 61, E749.	1.2	2

#	ARTICLE	IF	CITATIONS
397	Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 166, 729-735.	0.8	32
398	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 164-169.	1.9	40
399	Changes in Left Ventricular Diastolic Function During Hemodialysis Sessions. <i>American Journal of Kidney Diseases</i> , 2013, 62, 549-556.	2.1	20
400	Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (Highly Sensitive Troponin T) and NT-proBNP) in Patients With Advanced Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 831-837.	0.7	86
401	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	1.2	159
402	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1498-1506.	1.2	352
403	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	1.2	397
404	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 29-39.	6.3	810
405	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. <i>European Heart Journal</i> , 2013, 34, 1424-1431.	1.0	451
406	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	1.7	118
407	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	2.9	49
408	Ventricular dysfunction in a family with long QT syndrome type 3. <i>Europace</i> , 2013, 15, 1516-1521.	0.7	15
409	Trial data resolve gaps in evidence-based treatment. <i>Nature Reviews Cardiology</i> , 2013, 10, 67-68.	6.1	0
410	Neurohormonal and clinical sex differences in heart failure. <i>European Heart Journal</i> , 2013, 34, 2538-2547.	1.0	83
411	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
412	EUR-ICD Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	2.9	645
413	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
414	Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2012, 7, 1615-1623.	2.2	87

#	ARTICLE	IF	CITATIONS
415	The <i>European Heart Journal</i> and the <i>European Journal of Heart Failure</i>: partners in scientific publishing. <i>European Journal of Heart Failure</i> , 2012, 14, 1075-1082.	2.9	6
416	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	2.9	115
417	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
418	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1387-1395.	6.3	990
419	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 282-289.	1.2	71
420	Why do drugs for acute heart failure fail?. <i>European Journal of Heart Failure</i> , 2012, 14, 955-956.	2.9	17
421	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
422	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
423	The role of the kidney in heart failure. <i>European Heart Journal</i> , 2012, 33, 2135-2142.	1.0	209
424	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	1.4	40
425	Functional and Hemodynamic Cardiac Determinants of Exercise Capacity in Patients With Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 1336-1341.	0.7	20
426	The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 883.	0.7	5
427	Urinary Proteins in Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 44-55.	1.6	31
428	Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. <i>Heart Failure Reviews</i> , 2012, 17, 221-228.	1.7	38
429	Current and novel renal biomarkers in heart failure. <i>Heart Failure Reviews</i> , 2012, 17, 241-250.	1.7	38
430	The puzzle of kidney dysfunction in heart failure: an introduction. <i>Heart Failure Reviews</i> , 2012, 17, 129-131.	1.7	6
431	Comparison of Cardiac Positron Emission Tomography Perfusion Defects During Stress Induced by Hemodialysis Versus Adenosine. <i>American Journal of Kidney Diseases</i> , 2012, 59, 862-864.	2.1	8
432	Vitamin D status and outcomes in heart failure patients. <i>European Journal of Heart Failure</i> , 2011, 13, 619-625.	2.9	147

#	ARTICLE	IF	CITATIONS
433	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€RELAXâ€CAHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	2.9	99
434	Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2233-2241.	1.2	121
435	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1899-1907.	1.2	125
436	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. <i>Annals of Medicine</i> , 2011, 43, 60-68.	1.5	506
437	Pregnancy in women with corrected tetralogy of Fallot: Occurrence and predictors of adverse events. <i>American Heart Journal</i> , 2011, 161, 307-313.	1.2	80
438	Depressive symptoms and inflammation in patients hospitalized for heart failure. <i>American Heart Journal</i> , 2011, 161, 1053-1059.	1.2	37
439	The Cardiorenal Syndrome in Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 144-153.	1.6	83
440	Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. <i>European Journal of Heart Failure</i> , 2011, 13, 76-82.	2.9	67
441	Grading diastolic left ventricular function. <i>European Journal of Heart Failure</i> , 2011, 13, 698-699.	2.9	3
442	Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 899-908.	2.9	101
443	Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2011, 13, 1111-1120.	2.9	119
444	Diabetes: a driver for heart failure. <i>Heart</i> , 2011, 97, 774-780.	1.2	35
445	Clinical outcome of renal tubular damage in chronic heart failureâ€€. <i>European Heart Journal</i> , 2011, 32, 2705-2712.	1.0	174
446	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	1.6	82
447	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	1.0	84
448	Predictive value of tissue Doppler imaging for left ventricular ejection fraction, remodelling, and infarct size after percutaneous coronary intervention for acute myocardial infarction. <i>European Journal of Echocardiography</i> , 2010, 11, 596-601.	2.3	16
449	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60â€day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , 2010, 12, 499-507.	2.9	59
450	Effects of Eprosartan on Diastolic Function and Neurohormones in Patients with Hypertension and Diastolic Dysfunction. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 33-40.	1.3	1

#	ARTICLE	IF	CITATIONS
451	Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study). <i>American Journal of Cardiology</i> , 2010, 105, 517-521.	0.7	5
452	A single dose of erythropoietin in ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 2593-2600.	1.0	144
453	Telomere length and outcome in heart failure. <i>Annals of Medicine</i> , 2010, 42, 36-44.	1.5	37
454	Endogenous Erythropoietin and Outcome in Heart Failure. <i>Circulation</i> , 2010, 121, 245-251.	1.6	56
455	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. <i>Heart</i> , 2010, 96, 1297-1302.	1.2	179
456	Telomere length and psychological well-being in patients with chronic heart failure. <i>Age and Ageing</i> , 2010, 39, 223-227.	0.7	50
457	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	2.9	88
458	Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. <i>European Journal of Heart Failure</i> , 2010, 12, 974-982.	2.9	140
459	The <i>European Journal of Heart Failure</i> in 2010: current impact factor, time to first decision, and number of submissions. <i>European Journal of Heart Failure</i> , 2010, 12, 895-897.	2.9	3
460	EUR Observational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	2.9	340
461	Bone marrow dysfunction in chronic heart failure patients. <i>European Journal of Heart Failure</i> , 2010, 12, 676-684.	2.9	86
462	Response to Letter Regarding Article, "Endogenous Erythropoietin and Outcome in Heart Failure". <i>Circulation</i> , 2010, 122, .	1.6	0
463	Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. <i>European Journal of Heart Failure</i> , 2010, 12, 397-403.	2.9	21
464	Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. <i>Cardiovascular Research</i> , 2010, 87, 30-39.	1.8	72
465	The (pro)renin receptor in health and disease. <i>Annals of Medicine</i> , 2010, 42, 13-18.	1.5	49
466	Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. <i>European Journal of Heart Failure</i> , 2010, 12, 294-300.	2.9	42
467	Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 348-353.	2.9	19
468	Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?. <i>European Journal of Heart Failure</i> , 2010, 12, 215-216.	2.9	5

#	ARTICLE	IF	CITATIONS
469	N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>European Heart Journal</i> , 2010, 31, 120-127.	1.0	103
470	The cardiopulmonary continuum systemic inflammation as a common soil™ of heart and lung disease. <i>International Journal of Cardiology</i> , 2010, 145, 172-176.	0.8	58
471	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	13.9	473
472	Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 49-54.	1.0	12
473	Predictors of pregnancy complications in women with congenital heart disease. <i>European Heart Journal</i> , 2010, 31, 2124-2132.	1.0	538
474	Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure. <i>Circulation</i> , 2009, 120, 35-41.	1.6	39
475	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. <i>European Heart Journal</i> , 2009, 30, 1331-1339.	1.0	85
476	Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). <i>European Journal of Heart Failure</i> , 2009, 11, 847-854.	2.9	157
477	C-terminal pro-vasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. <i>European Heart Journal</i> , 2009, 30, 1187-1194.	1.0	198
478	Differential associations between renal function and a modifiable risk factors in patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2009, 98, 121-129.	1.5	101
479	Vasodilators in the treatment of acute heart failure: what we know, what we don't. <i>Heart Failure Reviews</i> , 2009, 14, 299-307.	1.7	52
480	Relaxin, a pleiotropic vasodilator for the treatment of heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 321-329.	1.7	113
481	Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 769-774.	1.4	17
482	Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. <i>International Journal of Cardiology</i> , 2009, 131, 336-344.	0.8	25
483	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. <i>American Heart Journal</i> , 2009, 157, 91-96.	1.2	13
484	Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 582-588.	1.2	796
485	Galectin-3: a novel mediator of heart failure development and progression. <i>European Journal of Heart Failure</i> , 2009, 11, 811-817.	2.9	434
486	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet</i> , The, 2009, 373, 1429-1439.	6.3	387

#	ARTICLE	IF	CITATIONS
487	Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 265-274.	1.3	51
488	Advanced Glycation Endproducts in Chronic Heart Failure. <i>Annals of the New York Academy of Sciences</i> , 2008, 1126, 225-230.	1.8	38
489	Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. <i>American Journal of Cardiology</i> , 2008, 102, 223-225.	0.7	5
490	Possible Association Between Telomere Length and Renal Dysfunction in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 207-210.	0.7	44
491	Effects of oral appliances and CPAP on the left ventricle and natriuretic peptides. <i>International Journal of Cardiology</i> , 2008, 128, 232-239.	0.8	46
492	Excellent Long-Term Clinical Outcome After Coronary Artery Bypass Surgery Using Three Pedicled Arterial Grafts in Patients With Three-Vessel Disease. <i>Annals of Thoracic Surgery</i> , 2008, 85, 508-512.	0.7	13
493	Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). <i>American Heart Journal</i> , 2008, 155, 817-822.	1.2	52
494	Skin-Autofluorescence, a Measure of Tissue Advanced Glycation End-Products (AGEs), is Related to Diastolic Function in Dialysis Patients. <i>Journal of Cardiac Failure</i> , 2008, 14, 596-602.	0.7	43
495	Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. <i>European Heart Journal</i> , 2008, 29, 1510-1515.	1.0	72
496	Overview of emerging pharmacologic agents for acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2008, 10, 201-213.	2.9	39
497	Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 997-1000.	2.9	181
498	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <i>European Journal of Heart Failure</i> , 2008, 10, 22-29.	2.9	72
499	Anemia in chronic heart failure: etiology and treatment options. <i>Current Opinion in Cardiology</i> , 2008, 23, 141-147.	0.8	25
500	Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2007, 9, 872-878.	2.9	393
501	Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 787-794.	2.9	82
502	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <i>European Heart Journal</i> , 2007, 28, 2018-2027.	1.0	210
503	Clinical and prognostic value of advanced glycation end-products in chronic heart failure. <i>European Heart Journal</i> , 2007, 28, 2879-2885.	1.0	76
504	Vascular benefits of angiotensin receptor blockers. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 987-997.	1.9	4

#	ARTICLE	IF	CITATIONS
505	Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 177-180.	1.0	5
506	An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the losartan intervention for endpoint reduction (LIFE) study adapted to The Netherlands. <i>Clinical Therapeutics</i> , 2007, 29, 963-971.	1.1	11
507	Î²-Adrenoceptor Antagonists in Elderly Patients with Heart Failure. <i>Drugs and Aging</i> , 2007, 24, 1031-1044.	1.3	14
508	Nebivolol: third-generation Î²-blockade. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1539-1550.	0.9	32
509	Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. <i>European Journal of Heart Failure</i> , 2007, 9, 1146-1155.	2.9	224
510	Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1459-1464.	1.2	257
511	Outcome of Pregnancy in Women With Congenital Heart Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2303-2311.	1.2	545
512	Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301-2302.	1.2	17
513	Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2007, 13, 599-608.	0.7	527
514	Prognostic Value of Pulse Pressure in Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 694.	0.7	1
515	Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2007, 100, 1548-1551.	0.7	18
516	Erythropoietin in Chronic Heart Failure. <i>Congestive Heart Failure</i> , 2007, 13, 289-292.	2.0	11
517	Renal Function Dependent Association of AGTR1 Polymorphism (A1166C) and Electrocardiographic Left-Ventricular Hypertrophy. <i>American Journal of Hypertension</i> , 2007, 20, 1097-1103.	1.0	18
518	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. <i>Current Heart Failure Reports</i> , 2007, 4, 127-133.	1.3	9
519	Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands. <i>Journal of Medical Economics</i> , 2006, 9, 121-131.	1.0	4
520	Serum Erythropoietin Levels and Infarct Size. <i>Journal of the American College of Cardiology</i> , 2006, 47, 468-469.	1.2	3
521	Protective Effects of Erythropoietin in Cardiac Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2161-2167.	1.2	167
522	Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. <i>International Journal of Cardiology</i> , 2006, 107, 73-77.	0.8	6

#	ARTICLE	IF	CITATIONS
523	Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. <i>International Journal of Cardiology</i> , 2006, 108, 63-67.	0.8	21
524	Obstetric complications in Marfan syndrome. <i>International Journal of Cardiology</i> , 2006, 110, 53-59.	0.8	106
525	The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 69-73.	1.3	10
526	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 135-141.	1.3	176
527	Usefulness of Preoperative C-Reactive Protein and Soluble Intercellular Adhesion Molecule-1 Level for Predicting Future Cardiovascular Events After Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 1697-1701.	0.7	19
528	Fertility, Pregnancy, and Delivery After Biventricular Repair for Pulmonary Atresia With an Intact Ventricular Septum. <i>American Journal of Cardiology</i> , 2006, 98, 259-261.	0.7	10
529	Pregnancy After Biventricular Repair for Pulmonary Atresia With Ventricular Septal Defect. <i>American Journal of Cardiology</i> , 2006, 98, 262-266.	0.7	13
530	Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 98, 751-753.	0.7	8
531	Statins in the Treatment of Chronic Heart Failure: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e333.	3.9	44
532	Statins in the treatment of chronic heart failure: Biological and clinical considerations. <i>Cardiovascular Research</i> , 2006, 71, 443-454.	1.8	44
533	Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction. <i>Circulation</i> , 2006, 114, 1572-1580.	1.6	277
534	Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 379-384.	1.1	20
535	Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. <i>European Heart Journal</i> , 2006, 28, 166-171.	1.0	134
536	Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. <i>Hypertension</i> , 2006, 48, 870-876.	1.3	16
537	Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 88-98.	0.8	18
538	Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1361-1364.	0.7	39
539	Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 330-335.	0.4	47
540	Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 119-124.	1.3	9

#	ARTICLE	IF	CITATIONS
541	Statins and Autonomic Function in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 167-168.	1.3	3
542	Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. <i>European Journal of Heart Failure</i> , 2005, 7, 81-86.	2.9	90
543	High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, 145-150.	1.0	5
544	Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. <i>Circulation</i> , 2005, 112, 1743-1747.	1.6	120
545	Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 1759-1764.	1.0	71
546	Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. <i>European Heart Journal</i> , 2005, 26, 2581-2587.	1.0	69
547	Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2005, 26, 2361-2367.	1.0	31
548	Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. <i>European Heart Journal</i> , 2005, 26, 2588-2595.	1.0	118
549	Hemoglobin levels and 30-day mortality in patients after myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 100, 289-292.	0.8	70
550	Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 125-133.	1.2	232
551	Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. <i>American Journal of Hypertension</i> , 2005, 18, 342-347.	1.0	35
552	The VEGF +405 CC Promoter Polymorphism is Associated With an Impaired Prognosis in Patients With Chronic Heart Failure: A MERIT-HF Substudy. <i>Journal of Cardiac Failure</i> , 2005, 11, 279-284.	0.7	55
553	High Prevalence of Microalbuminuria in Chronic Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2005, 11, 602-606.	0.7	48
554	Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 130-134.	1.0	15
555	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. <i>Circulation</i> , 2004, 110, 2809-2816.	1.6	489
556	Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 161-168.	1.0	3
557	Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting. <i>Hypertension</i> , 2004, 44, 930-934.	1.3	15
558	Erythropoietin in cardiovascular diseases. <i>European Heart Journal</i> , 2004, 25, 285-291.	1.0	136

#	ARTICLE	IF	CITATIONS
559	Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. <i>American Journal of Cardiology</i> , 2004, 94, 240-243.	0.7	42
560	Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 63-67.	1.2	178
561	Differences Between Angiotensin-Converting Enzyme Inhibition and Angiotensin II-AT1 Antagonism on Angiotensin-Mediated Responses in Human Internal Mammary Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 178-184.	0.8	9
562	Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model. <i>European Journal of Heart Failure</i> , 2002, 4, 277-282.	2.9	0
563	Functional antagonism of different angiotensin II type I receptor blockers in human arteries. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 311-316.	1.3	9
564	Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). <i>American Journal of Cardiology</i> , 2001, 87, 542-546.	0.7	135
565	Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. <i>Cardiovascular Drugs and Therapy</i> , 2000, 14, 55-60.	1.3	23
566	Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries. <i>Hypertension</i> , 2000, 35, 717-721.	1.3	149
567	Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2047-2053.	1.2	27
568	Dual pathway for angiotensin II formation in human internal mammary arteries. <i>British Journal of Pharmacology</i> , 1998, 125, 1028-1032.	2.7	62
569	Low Recurrence of Angina Pectoris After Coronary Artery Bypass Graft Surgery With Bilateral Internal Thoracic and Right Gastroepiploic Arteries. <i>Circulation</i> , 1998, 97, 2402-2405.	1.6	76
570	Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. <i>Cardiovascular Research</i> , 1997, 34, 568-574.	1.8	14
571	Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation. <i>American Journal of Cardiology</i> , 1997, 79, 1350-1354.	0.7	9
572	Progression of atherosclerosis after venous coronary artery bypass graft surgery: A 15-year follow-up study. , 1997, 41, 141-150.		14
573	Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2607-2609.	1.6	23
574	Long-term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age. <i>American Journal of Cardiology</i> , 1996, 77, 690-695.	0.7	26
575	Exclusive use of arterial grafts in coronary artery bypass operations for three-vessel disease: Use of both thoracic arteries and the gastroepiploic artery in 256 consecutive patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 112, 935-942.	0.4	55
576	Smoking and Cardiac Events After Venous Coronary Bypass Surgery. <i>Circulation</i> , 1996, 93, 42-47.	1.6	107